Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Hldgs is currently undervalued based on the offered purchase price of $21.80 per share by Garda Therapeutics, which reflects a potential upside for investors. However, potential risks such as delays in the transaction or regulatory issues could impact the realization of this value and should be carefully considered. Additionally, the recent impairment of intangible assets by $40932736 highlights the potential volatility in the company's financials and emphasizes the need for caution in investing in this stock.

Bears say

Assertio Hldgs is being sold to privately-held Garda Therapeutics for $18 per share, representing a 46.6% premium to the 30-day unaffected volume-weighted average price and a 21.1% premium to Garda's initial offer. This decision comes after multiple parties were considered during Assertio's "window-shop" period, indicating a lack of confidence in its core products. Additionally, the company's recent reverse stock split and loss on impairment of intangible assets further highlight its financial struggles.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.